Physician profile
Mohammad Elbatta
NPI 1316204894
$704.43
in general payments reported to CMS, 2019-2025
15 companies · $53.64 in 2025
The $53.64 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.00 · 2020: $16.07 · 2021: $118 · 2022: $16.80 · 2023: $280 · 2024: $197 · 2025: $53.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513 · Education: $18.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.50 |
| Education | $18.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200.81 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.30 | 2023 | Gattex, Entyvio |
| Pfizer INC. | $99.36 | 2024-2025 | |
| Madrigal Pharmaceuticals | $47.33 | 2024 | Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.20 | 2023 | Xifaxan |
| Genzyme Corporation | $26.40 | 2024 | |
| Novo Nordisk INC | $25.34 | 2025 | Wegovy |
| Gilead Sciences, INC. | $24.77 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.90 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $22.42 | 2023 | Rebyota |
| Sanofi-Aventis U.S. LLC | $22.00 | 2019 | |
| Evoke Pharma, INC. | $19.22 | 2023 | Gimoti |
| Exact Sciences Corporation | $19.03 | 2024 | Cologuard Collection Kit |
| Celltrion USA INC. | $18.62 | 2024 | Zymfentra |
| W. L. Gore & Associates, INC. | $15.73 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Elbatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.